1492 Capital Management’s NeoGenomics NEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-90,465
Closed -$4.87M 111
2020
Q4
$4.87M Sell
90,465
-30,632
-25% -$1.38M 2.81% 6
2020
Q3
$4.47M Buy
121,097
+1,667
+1% +$62K 3.34% 6
2020
Q2
$3.7M Sell
119,430
-38,284
-24% -$1.06M 3.17% 6
2020
Q1
$4.35M Sell
157,714
-4,740
-3% -$142K 5.21% 3
2019
Q4
$4.75M Buy
162,454
+11,698
+8% +$279K 4.2% 4
2019
Q3
$2.88M Sell
150,756
-937
-0.6% -$22K 2.81% 7
2019
Q2
$3.33M Sell
151,693
-117,795
-44% -$2.58M 3.11% 7
2019
Q1
$5.51M Sell
269,488
-26,478
-9% -$460K 4.67% 2
2018
Q4
$3.73M Sell
295,966
-63,329
-18% -$944K 3.35% 6
2018
Q3
$5.51M Sell
359,295
-1,238
-0.3% -$17.1K 3.59% 4
2018
Q2
$4.73M Sell
360,533
-4,231
-1% -$46.6K 3.38% 4
2018
Q1
$2.98M Sell
364,764
-10,478
-3% -$84.9K 2.29% 11
2017
Q4
$3.33M Sell
375,242
-2,178
-0.6% -$20.1K 2.59% 9
2017
Q3
$4.2M Sell
377,420
-3,977
-1% -$38.7K 3.71% 3
2017
Q2
$3.42M Sell
381,397
-104,918
-22% -$833K 3.01% 6
2017
Q1
$3.84M Sell
486,315
-10,150
-2% -$82.7K 2.98% 7
2016
Q4
$4.25M Sell
496,465
-38,988
-7% -$334K 3.28% 4
2016
Q3
$4.4M Sell
535,453
-23,570
-4% -$198K 3.6% 2
2016
Q2
$4.5M Sell
559,023
-134,770
-19% -$1.08M 4.04% 3
2016
Q1
$4.68M Sell
693,793
-59,310
-8% -$390K 3.95% 3
2015
Q4
$5.93M Sell
753,103
-126,270
-14% -$925K 4.31% 3
2015
Q3
$5.04M Buy
879,373
+35,068
+4% +$217K 3.59% 4
2015
Q2
$4.57M Sell
844,305
-46,487
-5% -$240K 2.89% 6
2015
Q1
$4.16M Buy
890,792
+104,297
+13% +$453K 2.41% 11
2014
Q4
$3.28M Buy
786,495
+27,373
+4% +$126K 2.05% 18
2014
Q3
$3.96M Buy
+759,122
New +$3.9M 2.19% 16

Other funds holding NEO

1492 Capital Management's NEO Position: Q1 2021 in Review

1492 Capital Management sold out of NeoGenomics (NEO) in Q1 2021, closing a stake of 90,465 shares — an estimated $4.87M sold.

1492 Capital Management first reported a position in NEO in Q3 2014 and held it in 26 quarters. The position peaked at $5.93M in Q4 2015. 332 funds tracked by Wall St. Rank hold NEO as of Q1 2021.

  • 1492 Capital Management reported no remaining NeoGenomics position as of Q1 2021 after selling out during the quarter.
  • 1492 Capital Management sold 90,465 NeoGenomics shares in Q1 2021, an estimated $4.87M.
  • 1492 Capital Management first reported a position in NeoGenomics in Q3 2014 and held it in 26 quarters.
  • 1492 Capital Management's NeoGenomics position peaked at $5.93M in Q4 2015.
  • 332 funds tracked by Wall St. Rank held NeoGenomics as of Q1 2021.

Based on 1492 Capital Management's 13F filing for Q1 2021, filed 12 May 2021.